

## DAFTAR PUSTAKA

- Abubakar, M., Sung, H., Bcr, D., Guida, J., Tang, T.S., Pfeiffer, R.M., Yang, X.R., 2018. Breast cancer risk factors, survival and recurrence, and tumor molecular subtype: Analysis of 3012 women from an indigenous Asian population. *Breast Cancer Res.* **20**: 1–14. doi:10.1186/s13058-018-1033-8
- Amandito, R., Viryawan, C., Santoso, F., Gautami, W., Panigoro, S.S., 2013. The characteristics of breast cancer patients in Dharmas Hospital National Cancer Center Jakarta based on occupational and environmental status. *Indones. J. Cancer* **7**: 53–59.
- American Cancer Society, 2014. Breast Cancer. Available at: <http://www.breastcancer.org>.
- American Joint Committee on Cancer, 2017. AJCC Breast Cancer Staging System on AJCC Cancer Staging Manual, Eight Edition. Chicago, Illinois: The American College of Surgeons (ACS).
- Andreopoulou, E., Sparano, J.A., 2013. Chemotherapy in patients with anthracycline and taxane-pretreated metastatic breast cancer: An overview. *Curr. Breast Cancer Rep.* **5**: 42–50. doi:10.1007/s12609-012-0097-1
- Angahar, L.T., 2017. An Overview of Breast Cancer Epidemiology, Risk Factors, Pathophysiology, and Cancer Risks Reduction. *MOJ Biol. Med.* **1**: 92–96. doi:10.15406/mojbm.2017.01.00019
- Bartsch, R., Bergen, E., Galid, A., 2018. Current concepts and future directions in neoadjuvant chemotherapy of breast cancer. *Memo - Mag. Eur. Med. Oncol.* **11**: 199–203. doi:10.1007/s12254-018-0421-1
- Bewick, V., Cheek, L., Ball, J., 2004. Statistics review 12: Survival analysis. *Crit. Care* **8**: 389–394. doi:10.1186/cc2955
- Brandt, J., Garne, P.P., Tengrup, I., Manjer, J., 2015. Age at diagnosis in relation to survival following breast cancer: A cohort study. *World J. Surg. Oncol.* **13**: 1–11. doi:10.1186/s12957-014-0429-x
- Burstein, H.J., 2018. Adjuvant chemotherapy for HER2-negative breast cancer.
- Caplan, L., 2014. Delay in breast cancer: Implications for stage at diagnosis and survival. *Front. Public Heal.* **2**: 1–5. doi:10.3389/fpubh.2014.00087
- Cecchini, R.S., Swain, S.M., Costantino, J.P., Rastogi, P., Jeong, J.H., Anderson, S.J., Tang, G., Geyer, C.E., Lembersky, B.C., Romond, E.H., Paterson, A.H.G., Wolmark, N., 2016. Body mass index at diagnosis and breast cancer survival prognosis in clinical trial populations from NRG oncology/NSABP B-30, B-31, B-34, and B-38. *Cancer Epidemiol. Biomarkers Prev.* **25**: 51–59. doi:10.1158/1055-9965.EPI-15-0334-T

- Chen, Y., Shi, X.E., Tian, J.H., Yang, X.J., Wang, Y.F., Yang, K.H., 2018. Survival benefit of neoadjuvant chemotherapy for resectable breast cancer. *Med. (United States)* 97. doi:10.1097/MD.00000000000010634
- Chen, H.L., Zhou, M.Q., Tian, W., Meng, K.X., He, H.F., 2016. Effect of age on breast cancer patient prognoses: A population-based study using the SEER 18 database. *PLoS One* 11: 1–11. doi:10.1371/journal.pone.0165409
- Chirivella, I., Bermejo, B., Insa, A., Pérez-Fidalgo, A., Magro, A., Rosello, S., García-Garre, E., Martín, P., Bosch, A., Lluch, A., 2009. Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. *Breast Cancer Res. Treat.* 114: 479–484. doi:10.1007/s10549-008-0018-1
- Chisholm-Burns, M.A., Schwinghammer, T.L., Wells, B.G., Malone, P.M., Jill M. Kolesar, P., DiPiro, J.T., 2016. *Pharmacotherapy: Principles & Practice*, 4th ed. McGraw-Hill Education.
- Cianfrocca, M. dan Goldstein, L.J., 2004. Prognostic and Predictive Factors in Early-Stage Breast Cancer. *The Oncologist, Breast Cancer*, 9: 606–616.
- Dahlan, M.S., 2012. *Analisis Survival: Dasar-Dasar Teori dan Aplikasi Program Stata Edisi II*, Jakarta: Sagung Seto.
- Denduluri, N., Lyman, G.H., Wang, Y., Morrow, P.K., Barron, R., Patt, D., Bhowmik, D., Li, X., Bhor, M., Fox, P., Dhanda, R., Saravanan, S., Jiao, X., Garcia, J., Crawford, J., 2018. Chemotherapy Dose Intensity and Overall Survival Among Patients With Advanced Breast or Ovarian Cancer. *Clin. Breast Cancer* 18: 380–386. doi:10.1016/j.clbc.2018.02.003
- DiPiro, C.V., 2015. ‘Breast Cancer’ in DiPiro, J.T., Talbert, Gary R., Y., Barbara G., W., I.Michael, P., *Pharmacotherapy Handbook*, 9th Edition. United States. pp 619-622
- DiPiro, J.T., Talbert, Gary R., Y., Barbara G., W., I.Michael, P., 2016. *Breast Cancer in Pharmacotherapy: A Pathophysiologic Approach* 10th Edition. Pharmacotherapy: A Pathophysiologic Approach 10th Edition.
- Dyanti, G.A.R., Suariyani, N.L.P., 2016. Faktor-Faktor Keterlambatan Penderita Kanker Payudara Dalam Melakukan Pemeriksaan Awal Ke Pelayanan Kesehatan. *J. Kesehat. Masy.* 11: 276. doi:10.15294/kemas.v11i2.3742
- Ewertz, M., Land, L.H., Dalton, S.O., Jensen, M., Ewertz, M., Land, L.H., Dalton, S.O., Cronin, D., 2018. Influence of specific comorbidities on survival after early-stage breast cancer. *Acta Oncol. (Madr)*. 0: 129–134. doi:10.1080/0284186X.2017.1407496
- Fiteni, F., Westeel, V., Pivot, X., Borg, C., Vernerey, D., Bonnetain, F., 2014. Endpoints in cancer clinical trials. *J. Visc. Surg.* 151: 17–22.

doi:10.1016/j.jviscsurg.2013.10.001

- Gadisa, D.A., Assefa, M., Tefera, G.M., Yimer, G., 2020. Patterns of Anthracycline-Based Chemotherapy-Induced Adverse Drug Reactions and Their Impact on Relative Dose Intensity among Women with Breast Cancer in Ethiopia: A Prospective Observational Study. *J. Oncol.* 2020: 1–12. doi:10.1155/2020/2636514
- Gayatri, D., 2005. Mengenal Analisis Ketahanan (Survival Analysis). *J. Keperawatan Indones.* **9**: 36–40. doi:10.7454/jki.v9i1.158
- Gradishar, W.J., Anderson, B.O., Balassanian, R., Blair, S.L., Burstein, H.J., Cyr, A., dkk., 2017. NCCN Guidelines Insights: Breast Cancer, Version 1.2017. *Journal of the National Comprehensive Cancer Network*, **15**: 433–451.
- Gunasekaran, G.H., Hassali, M.A.B.A., Sabri, W.M.A.B.W., Rahman, M.T. Bin, 2020. Impact of chemotherapy schedule modification on breast cancer patients: a single-centre retrospective study. *Int. J. Clin. Pharm.* **42**: 642–651. doi:10.1007/s11096-020-01011-6
- Harbeck, N., Gluz, O., 2017. Neoadjuvant therapy for triple negative and HER2-positive early breast cancer. *Breast* **34**: S99–S103. doi:10.1016/j.breast.2017.06.038
- Holmes, D., Colfry, A., Czerniecki, B., Dickson-Witmer, D., Francisco Espinel, C., Feldman, E., Gallagher, K., Greenup, R., Herrmann, V., Kuerer, H., Malik, M., Manahan, E., O'Neill, J., Patel, M., Sebastian, M., Wheeler, A., Kass, R., 2015. Performance and Practice Guideline for the Use of Neoadjuvant Systemic Therapy in the Management of Breast Cancer. *Ann. Surg. Oncol.* **22**: 3184–3190. doi:10.1245/s10434-015-4753-3
- Ithimakin, S., Chuthapisith, S., 2013. Neoadjuvant chemotherapy for breast cancer. *Chinese J. Oncol.* **23**: 423–425. doi:10.5772/53124
- Jatoi, I., Kaufmann, M., 2010, *Management of Breast Diseases*, 1th Edition, Springer, Berlin, pp 121-130.
- John, P., Osani, M.C., Kodali, A., Buchsbaum, R., Bannuru, R.R., Erban, J.K., 2021. Comparative Effectiveness of Adjuvant Chemotherapy in Early-Stage Breast Cancer: A Network Meta-analysis. *Clin. Breast Cancer* **21**: e22–e37. doi:10.1016/j.clbc.2020.07.005
- Karimi, A., Delpisheh, A., Sayehmiri, K., Saboori, H., Rahimi, E., 2014. Predictive factors of survival time of breast cancer in Kurdistan province of Iran between 2006-2014: A cox regression approach. *Asian Pacific J. Cancer Prev.* **15**: 8483–8488. doi:10.7314/APJCP.2014.15.19.8483
- Kementerian Kesehatan RI. 2016, InfoDatin Kemenkes RI – Bulan Peduli Kanker payudara

- Kementerian Kesehatan RI, 2019. *Peringatan Hari Kanker Se-Dunia*, Departemen Kesehatan Republik Indonesia, Jakarta.
- Kishore, J., Goel, M., Khanna, P., 2010. Understanding survival analysis: Kaplan-Meier estimate. *Int. J. Ayurveda Res.* 1: 274. doi:10.4103/0974-7788.76794
- Koda-Kimble, M.A., Alldredge, B.K. (Eds.), 2013. *Applied therapeutics: the clinical use of drugs*, 10th ed. Wolters Kluwer/Lippincott Williams & Wilkins, Philadelphia.
- Kogan, L.G., Davis, S.L., Brooks, G.A., 2019. Treatment delays during FOLFOX chemotherapy in patients with colorectal cancer: A multicenter retrospective analysis. *J. Gastrointest. Oncol.* 10: 841–846. doi:10.21037/jgo.2019.07.03
- Lafourcade, A., His, M., Baglietto, L., Boutron-Ruault, M.-C., Dossus, L., Rondeau, V., 2018. Factors associated with breast cancer recurrences or mortality and dynamic prediction of death using history of cancer recurrences: the French E3N cohort. *BMC Cancer* 18. <https://doi.org/10.1186/s12885-018-4076-4>
- Liutkauskiene, S., Grizas, S., Jureniene, K., Suipyte, J., Statnickaite, A., Juozaityte, E., 2018. Retrospective analysis of the impact of anthracycline dose reduction and chemotherapy delays on the outcomes of early breast cancer molecular subtypes. *BMC Cancer* 18: 1–9. doi:10.1186/s12885-018-4365-y
- Iyengar, N.M., Arthur, R., Manson, J.E., Chlebowski, R.T., Kroenke, C.H., Peterson, L., Cheng, T.Y.D., Feliciano, E.C., Lane, D., Luo, J., Nassir, R., Pan, K., Wassertheil-Smoller, S., Kamensky, V., Rohan, T.E., Dannenberg, A.J., 2019. Association of Body Fat and Risk of Breast Cancer in Postmenopausal Women with Normal Body Mass Index: A Secondary Analysis of a Randomized Clinical Trial and Observational Study. *JAMA Oncol.* 5: 155–163. doi:10.1001/jamaoncol.2018.5327
- Lyman, G.H., Dale, D.C., Crawford, J., 2003. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: A nationwide study of community practices. *J. Clin. Oncol.* 21: 4524–4531. doi:10.1200/JCO.2003.05.002
- Ma, C., 2014. Role of pharmacists in optimizing the use of anticancer drugs in the clinical setting. *Integr. Pharm. Res. Pract.* 11. doi:10.2147/iprp.s40428
- Masood, S., 2016. Neoadjuvant chemotherapy in breast cancers. *Women's Heal.* 12: 480–491. doi:10.1177/1745505716677139
- Mavroudis, D., Matikas, A., Malamos, N., Papakotoulas, P., Kakolyris, S., Boukovinas, I., Athanasiadis, A., Kentepozidis, N., Ziras, N., Katsaounis, P., Saloustros, E., Georgoulas, V., 2016. Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: A

- multicenter randomized study by the Hellenic Oncology Research Group (HOR. *Ann. Oncol.* 27: 1873–1878. doi:10.1093/annonc/mdw274
- Mayo Clinic, 2019. Recurrent breast cancer - Symptoms and causes [WWW Document]. Mayo Clinic. URL <https://www.mayoclinic.org/diseases-conditions/recurrent-breast-cancer/symptoms-causes/syc-20377135> (accessed 26.4.22).
- Mcpherson, K., Steel, C.M., Dixon, J.M., 2000. ABC of breast diseases: Breast cancer—epidemiology, risk factors, and genetics. *Bmj* 321: 1198.
- Motzer, R.J., Geller, N.L., George, J., 1990. The Effect of a 7-Day Delay in Chemotherapy Cycles on Complete Response and Event-Free Survival in Good-Risk Disseminated Germ Cell Tumor Patients. *Cancer* 66: 857–861.
- Munsell, M.F., Sprague, B.L., Berry, D.A., Chisholm, G., Trentham-Dietz, A., 2014. Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status. *Epidemiol. Rev.* 36: 114–136. doi:10.1093/epirev/mxt010
- National Cancer Institute, 2019. Definition of overall survival – NCI Dictionary of Cancer Terms – National Cancer Institute [WWW Document]. URL <https://www.cancer.gov/publications/dictionaries/cancer-term/def/overall-survival> (accessed 26.4.22).
- Ntellas, P., Spathas, N., Agelaki, S., Zintzaras, E., 2019. Taxane & cyclophosphamide vs anthracycline & taxane-based chemotherapy as adjuvant treatment for breast cancer : a pooled analysis of randomized controlled trials by the Hellenic Academy of Oncology. *Oncotarget* 10: 1209–1216.
- Ording, A.G., Garne, J.P., Nyström, P.M.W., Frøslev, T., Sørensen, H.T., Lash, T.L., 2013. Comorbid Diseases Interact with Breast Cancer to Affect Mortality in the First Year after Diagnosis-A Danish Nationwide Matched Cohort Study. *PLoS One* 8: 1–8. doi:10.1371/journal.pone.0076013
- Pane M, 2002, Aspek Klinis dan Epidemiologis Penyakit kanker Payudara, *Jurnal Kedokteran dan Farmasi Medika*, 28(8), 17-22.
- Park, Y., 2011. Current status of therapy for breast cancer worldwide and in Japan. *World J. Clin. Oncol.* 2: 125. doi:10.5306/wjco.v2.i2.125
- Patnaik, J.L., Byers, T., Diguseppi, C., Denberg, T.D., Dabelea, D., 2011. The Influence of Comorbidities on Overall Survival Among Older Women Diagnosed With Breast Cancer 1101–1111. doi:10.1093/jnci/djr188
- Purwanto, H., Handojo, D., Haryono, S.J., dan Harahap, W.A. (ed). 2014. *Panduan Penatalaksanaan Kanker Payudara*, PERABOI, Jakarta.
- Qi, W., Wang, X., Gan, L., Li, Y., Li, H., Cheng, Q., 2020. The effect of reduced

RDI of chemotherapy on the outcome of breast cancer patients. *Sci. Rep.* 10: 1–13. doi:10.1038/s41598-020-70187-8

Rich, J.T., Neeley, J.G., Paniello, R.C., Voelker, C.C.J., Oxon, D.P., Nussenbaum, B., Wang, E.W., 2010. A Practical Guid to Understanding Kaplan-Meier Curves. *J. Otolaryngol. - Head Neck Surg.* **143**: 331–336. doi:10.1016/j.otohns.2010.05.007.A

Ruddon, H.L., 2007. *Cancer Biology*, Fourth edition, Oxford University Press, New York

Satroasmoro, S. dan Ismael, S., 2011. *Dasar - Dasar Metodologi Penelitian Klinis*, 4. Sagung Seto, Jakarta.

Schoenfeld, D.A., 1983. Regression Sample-Size Formula for the Proportional-Hazards Model 39: 499–503.

Seebacher, V., Reinthaller, A., Koelbl, H., Concin, N., Nehoda, R., Polterauer, S., 2017. The impact of the duration of adjuvant chemotherapy on survival in patients with epithelial ovarian cancer - A retrospective study. *PLoS One* 12: 1–11. doi:10.1371/journal.pone.0169272

Sinaga, E.S., Ahmad, R.A., Hutajulu, S.H., 2017. Analisis ketahanan hidup 5 tahun pada pasien kanker payudara di RS Sardjito provinsi Yogyakarta, Indonesia. *Berita Kedokteran Masyarakat*, **33** No.2.

Street, W., 2020. Breast Cancer Facts & Figures 2019-2020. American Cancer Society, Inc. Atlanta, Georgia. 44.

Street, W., 2017. Breast Cancer Facts & Figures 2017-2018. American Cancer Society 44.

Sun, L., Zhu, Y., Qian, Q., Tang, L., 2018. Body mass index and prognosis of breast cancer. *Med. (United States)* 97. doi:10.1097/MD.00000000000011220

Szabo, A., 2012. Internal Pilot Studies: An Annotated Bibliography 16.

Taucher, S., Steger, G.G., Jakesz, R., Tausch, C., Wette, V., Schippinger, W., Kwasny, W., Reiner, G., Greil, R., Dubsky, P., Poestlberger, S., Tschmelitsch, J., Samonigg, H., Gnant, M., 2008. The potential risk of neoadjuvant chemotherapy in breast cancer patients-results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07). *Breast Cancer Res. Treat.* 112: 309–316. doi:10.1007/s10549-007-9844-9

West, J., Newton, P.K., 2018. therapies 77: 6717–6728. doi:10.1158/0008-5472.CAN-17-1120.Chemotherapeutic



- Whitehead, A.L., Julious, S.A., Cooper, C.L., Campbell, M.J., 2016. Estimating the sample size for a pilot randomised trial to minimise the overall trial sample size for the external pilot and main trial for a continuous outcome variable. *Stat. Methods Med. Res.* 25: 1057–1073. doi:10.1177/0962280215588241
- Widiana, I.K., Irawan, H., 2020. Clinical and Subtypes of Breast Cancer in Indonesia. *Asian Pacific J. Cancer Care* 5: 281–285. doi:10.31557/apjcc.2020.5.4.281-285
- World Health Organization. 2019, *IARC Global Cancer Observatory Breast Cancer*, France, WHO
- Wu, Y., Aravind, S., Ranganathan, G., Martin, A., Nalysnyk, L., 2009. Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: A descriptive study of a large outpatient oncology practice database, 2000-2007. *Clin. Ther.* 31: 2416–2432. doi:10.1016/j.clinthera.2009.11.020
- Yersal, O., Barutca, S., 2014. Biological subtypes of breast cancer: Prognostic and therapeutic implications. *World J. Clin. Oncol.* 5: 412–424. doi:10.5306/wjco.v5.i3.412
- Yu, K. Da, Liu, X.Y., Chen, L., Mo, M., Wu, J., Liu, G.Y., Di, G.H., Verschraegen, C., Stover, D.G., Zhuang, Z.G., Bertucci, F., Orlandi, A., Wang, J., Lippi, G., Wu, K.J., Osman, M.A., Fan, L., Shao, Z.M., 2021. Anthracycline-free or short-term regimen as adjuvant chemotherapy for operable breast cancer: A phase III randomized non-inferiority trial. *Lancet Reg. Heal. - West. Pacific* 11. doi:10.1016/j.lanwpc.2021.100158
- Zaheed, M., Wilcken, N., Willson, M.L., O’connell, D.L., Goodwin, A., 2019. Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer. *Cochrane Database Syst. Rev.* 2019. doi:10.1002/14651858.CD012873.pub2
- Zheng, R., Han, S., Duan, C., Chen, K., You, Z., Jia, J., Lin, S., Liang, L., Liu, A., Long, H., Wang, S., 2015. Role of taxane and anthracycline combination regimens in the management of advanced breast cancer a meta-analysis of randomized trials. *Med. (United States)* 94: e803. doi:10.1097/MD.0000000000000803